Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer's Xeljanz Approval In UC Includes Postmarket Study On Long-Term Effects

Jun 03 2018

• By Derrick Gingery

FDA Approved typed words on a vintage typewriter

Related Content

Xeljanz's UC Indication On Track With Higher Doses After Unanimous Advisory Committee Votes

Mar 09 2018

US FDA Eliminating 'Sub-Indications' From Inflammatory Bowel Disease Labels

Mar 12 2018

Aimovig And Tegsedi In Raft Of Products To Get EMA Thumbs up

Jun 01 2018

Pfizer Xeljanz's Long-term Dosing Raises Safety Concerns In Ulcerative Colitis

Mar 07 2018

Pfizer Xeljanz: Duration Of 10 mg Dose In Ulcerative Colitis Could Hinge On Post-Market Commitment

Mar 11 2018

Could FDA Force Pfizer To Push Shingles Vaccination With Xeljanz Psoriatic Arthritis Approval?

Aug 18 2017

Pfizer's Xeljanz Pushed By New Tailwind From Approval In Ulcerative Colitis

May 30 2018

Related Companies

Pfizer Inc.

Additional Topics

United States Post Market Regulation & Studies Regulation Approvals FDA Gastrointestinal BioPharmaceutical

More from Post-Marketing Regulation & Studies

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window